ADA trims kid A1C levels

Share this article:
ADA trims kid A1C levels
ADA trims kid A1C levels

The American Diabetes Association is lowering the A1C ceiling for type 1 diabetes patients ages 18 and younger from 8.5% to 7.5%. The research organization announced the change Monday at the group's Scientific Sessions, the same day it published the supporting position statement in Diabetes Care.

The decision means the ADA's recommendations will fall in line with those of the International Society for Pediatric and Adolescent Diabetes, the Pediatric Endocrine Society and the International Diabetes Federation.

Until now the ADA allowed for variable glucose levels in which patients under the age of six could go as high as 8.5%, children between the ages of six and 12 could be 8.0%, and adolescents 7.5%.

Researchers said the previous guidelines “arose from a combination of two lines of unsubstantiated evidence,”  which predated innovations like insulin analogs and easily used glucometers. They write that the thinking at the time was that severe recurrent hypoglycemia accompanied by seizures or coma could have long-term consequences on brain development, but that high-ish glucose levels would not have long-term health consequences as long as they predated puberty.

Researchers note that recent studies show otherwise, and have failed to link neurocognitive decline with hypoglycemia among young children. Instead they report quite the opposite—that elevated glucose levels may “produce adverse outcomes in the short term on neurocognitive function.” They also note clinicians are increasingly thinking that keeping a lid on glucose levels before puberty may “reduce the risk for both micro- and macrovasular complications” later on.

Type 1 diabetes is associated with an increased risk for immunologic disorder celiac disease, and over- or under-active thyroids.

Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Thursday, August 21

Five things for pharma marketers to know: Thursday, ...

An Ebola survivor is set to leave Emory University Hospital, but the cause of the cure is uncertain, the FDA has approved a new type 1 diabetes test, and the ...

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Gaucher disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.